On Tuesday, September 3rd, we launched a new product, UroControl®, an innovative test for the early detection of relapses in non-muscle-invasive bladder cancer. Bioprofarma Bagó signed a promotional agreement with Argenomics to strengthen its Urology portfolio.
UroControl® is a liquid biopsy that, using advanced molecular biology techniques, detects key mutations in the TERT, FGFR3, and KRAS genes through a urine sample. This non-invasive approach provides patients and healthcare professionals with an additional tool to monitor cancer progression, improving decision-making and reducing the need for more invasive procedures.
At Bioprofarma Bagó, we remain committed to finding new alternatives that offer innovative and non-invasive solutions for our patients and healthcare professionals. We are proud to continue growing, providing cutting-edge technology that helps improve the quality of life for those who need it most.